TY - JOUR
T1 - Therapeutic Drug Monitoring in Inflammatory Bowel Disease
T2 - History and Future Directions
AU - Spencer, Elizabeth A.
AU - Dubinsky, Marla C.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/12
Y1 - 2017/12
N2 - Clinical trials for the most effective drugs in the armamentarium of medications for inflammatory bowel disease (IBD) have shown only a 50-60% response rate, and this drops to 30% in maintenance. However, therapeutic drug monitoring (TDM) to adjust dosing to account for patient-specific characteristics, which has been shown to improve outcomes, was not utilized in these trials. This review will detail the development of TDM within the IBD space as it evolved from thiopurines to biologics and continues to evolve with loftier treat-to-target goals and more sophisticated dashboard systems.
AB - Clinical trials for the most effective drugs in the armamentarium of medications for inflammatory bowel disease (IBD) have shown only a 50-60% response rate, and this drops to 30% in maintenance. However, therapeutic drug monitoring (TDM) to adjust dosing to account for patient-specific characteristics, which has been shown to improve outcomes, was not utilized in these trials. This review will detail the development of TDM within the IBD space as it evolved from thiopurines to biologics and continues to evolve with loftier treat-to-target goals and more sophisticated dashboard systems.
KW - Biologics
KW - Inflammatory bowel disease
KW - Therapeutic drug monitoring
KW - Thiopurine metabolite monitoring
UR - http://www.scopus.com/inward/record.url?scp=85035031781&partnerID=8YFLogxK
U2 - 10.1016/j.pcl.2017.08.008
DO - 10.1016/j.pcl.2017.08.008
M3 - Review article
C2 - 29173787
AN - SCOPUS:85035031781
SN - 0031-3955
VL - 64
SP - 1309
EP - 1326
JO - Pediatric Clinics of North America
JF - Pediatric Clinics of North America
IS - 6
ER -